Login to Your Account


Topivert’s topical kinase program brings in $28M in second round

By Nuala Moran
Staff Writer

Friday, January 17, 2014
LONDON – Topivert Ltd. has raised £17 million (US$27.9 million) in a second funding round, providing the means to take its two lead topical kinase inhibitor programs to proof of concept and a hoped-for trade sale exit for the investors.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription